Newsmeme!
Discover News you didn't know existed
Identification of mutations in fibroblast growth factor receptor 4 (FGFR4) that are associated with Rhabdomyosarcoma tumors; may be used to identify candidates for treatment with an FGFR4 inhibitor as an adjuvant to standard anticancer therapy.
WOBURN, Mass.----ProChon Biotech, Ltd., an innovator of tissue regenerative technologies to relieve pain and restore the mobility and quality-of-life for sufferers of articular cartilage injuries, today announced that it received the Genzyme Award for Excellence in Cartilage Research for its poster presentation entitled, "Comparative Analysis of Cell Sources for Cartilage Cell Therapy."
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |